UCL School of Pharmacy
- About the School
- Study Here
- Master of Pharmacy (MPharm)
- MSc in Clinical Pharmacy, International Practice and Policy
- MSc in Drug Delivery
- MSc in Drug Discovery and Development
- MSc in Drug Discovery and Pharma Management
- MSc in Pharmacognosy
- MSc Experimental Pharmacology and Therapeutics
- Master of Research (MRes)
- Research Areas
- How to apply
- Entry requirements
- Tuition Fees
- PhD Studentships
- Next-generation sequencing in inhibitory synaptic disorders
- Nanoparticle self-association from inhaled microparticles
- Understanding the role of Ca2+ currents in influencing neuronal activity in entorhinal cortical neurons.
- Understanding the mechanisms of hyposmia in a novel model of early stage Parkinson's Disease (ESPD) and its reversal by exendin-4
- Structure-function studies of defective excitatory and inhibitory transmission in neurological disease
- New methods for exquisite control and quantification of amorphous pharmaceuticals
- High-throughput discovery of novel nanoparticulate vaccine adjuvants for humans
- Development of novel formulations to improve skin health
- The Development of Electrospun Nanofibrous Matrices for the Oral Delivery of Poorly Water Soluble Therapeutic Agents
- Scholarships & funding
- Pharmacy Practice (PG Dip/MSc)
- Certificate in Medicines Management for Pharmacy Technicians
- Clinical Pharmacy Summer School
- Research Themes
- News Archive
- Student Life
- International students
- Library and Services
- Research Departments
- Work Here
- Contact Us
- UCL School of Pharmacy News
Applications are invited for a 3 year funded PhD studentship in the laboratories of Dr. Andy Constanti and Dr. Peter Whitton at The UCL School of Pharmacy. The work in our laboratories is currently focused on investigating a new model of early stage Parkinson’s Disease (ESPD) with a particular focus on the mechanisms responsible for hyposmia, one of the so-called early ‘pre-motor’ symptoms exhibited by many PD patients and its reversal by exendin-4, a recently introduced anti-diabetic drug, also currently being evaluated in clinical trials as a novel treatment for PD. The proposed project will involve mainly neurochemical, histological and possibly also intracellular in vitro electrophysiological techniques, therefore will involve a variety of disciplines including neuropharmacology, immunocytochemistry and neurophysiology. The project will allow development of skills in these areas as appropriate. The successful candidate will work in an established laboratory currently funded by the Cure Parkinson’s Trust. The candidate will also have access to specialized training courses as required.
Applications are sought from candidates with a first or upper second class honours degree in Neuroscience, Pharmacology, Physiology, Biology, Biochemistry, Pharmacy or an equivalent subject. An MSc in Neuroscience or Pharmacology or a relevant industrial placement of 6 months or more are desirable though not a requirement.
This studentship is limited to students with Home/ EU tuition fee status and it covers the tuition fees and a maintenance stipend for three years. For 2012/13 the stipend rate is £15,590. The start date of the studentship is flexible but we would ideally wish to make an appointment to start from 8 April 2013 at the latest.
Informal enquiries may be addressed to
or Dr Peter Whitton:
Applications must include CV, personal statement plus the names of two referees and should be sent to Victor Diran.
Application closing date is 22 March 2013.
The UCL School of Pharmacy is committed to equality of opportunity and selection on merit.
Page last modified on 28 feb 13 17:18